These results suggest that reducing the levels or the activity of SREBP1 reduces cell proliferation through its direct effect on cyclin D1, while it also presents SREBP1 activation as a druggable target for reducing the risk of cancers driven by some oncogenes such as PI3K. The gene discussed is SREBF1; the disease is cancer.